ArticlePloS one2019
Antifungal activity of well-defined chito-oligosaccharide preparations against medically relevant yeasts.
Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Discovery of a multifunctional chitinase-cellulase from Thermococcus chitonophagus with expanded polysaccharide specificity.Biotechnology for biofuels and bioproducts · 2026Article
- Targeting Non-ACS omega · 2025Article
- Comparative Potential of Chitinase and Chitosanase from the StrainBiotech (Basel (Switzerland)) · 2025Article
- Vaginal prevention of Candida albicans: synergistic effect of lactobacilli and mannan oligosaccharides (MOS).Applied microbiology and biotechnology · 2024Article
- Possible Molecular Targeting of Biofilm-Associated Genes by Nano-Ag in Candida albicans.Applied biochemistry and biotechnology · 2024Article
- Green-Chemical Strategies for Production of Tailor-Made Chitooligosaccharides with Enhanced Biological Activities.Molecules (Basel, Switzerland) · 2023Review
- Biofilm-associated genes as potential molecular targets of nano-FePharmacological reports : PR · 2023Article
- Chitosan-induced biotic stress tolerance and crosstalk with phytohormones, antioxidants, and other signalling molecules.Frontiers in plant science · 2023Review
- Potential Medical Applications of Chitooligosaccharides.Polymers · 2022Review
- Synergistic Antimicrobial Activities of Chitosan Mixtures and Chitosan-Copper Combinations.International journal of molecular sciences · 2022Article
- Antimicrobial Activities of Chitosan Derivatives.Pharmaceutics · 2021Article
- Synergistic Antifungal Activity of Chito-Oligosaccharides and Commercial Antifungals on Biofilms of ClinicalJournal of fungi (Basel, Switzerland) · 2021Article
- Identification of Alkaloid Compounds Arborinine and Graveoline from Ruta angustifolia (L.) Pers for their Antifungal Potential against Isocitrate lyase (ICL1) gene of Candida albicans.Mycopathologia · 2021Article
- Production of Structurally Defined Chito-Oligosaccharides with a SingleJournal of agricultural and food chemistry · 2021Article
- Chitin and Chitosan Derivatives as Biomaterial Resources for Biological and Biomedical Applications.Molecules (Basel, Switzerland) · 2020Review
- Filling the Void: An Optimized Polymicrobial Interkingdom Biofilm Model for Assessing Novel Antimicrobial Agents in Endodontic Infection.Microorganisms · 2020Article
- Chitosan Ameliorates Candida auris Virulence in a Galleria mellonella Infection Model.Antimicrobial agents and chemotherapy · 2020Article
- Synthetic Naphthofuranquinone Derivatives Are Effective in Eliminating Drug-ResistantFrontiers in microbiology · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to their antifungal activity, chitosan and its derivatives have potential to be used for treating yeast infections in humans. However, to be considered for use in human medicine, it is necessary to control and know the chemical composition of the compound, which is not always the case for polymeric chitosans. Here, we analyze the antifungal activity of a soluble and well-defined chito-oligosaccharide (CHOS) with an average polymerization degree (DPn) of 32 and fraction of acetylation (FA) of 0.15 (C32) on 52 medically relevant yeast strains. Minimal inhibitory concentrations (MIC) varied widely among yeast species, strains and isolates (from > 5000 to < 9.77 μg mL-1) and inhibition patterns showed a time- and dose-dependencies. The antifungal activity was predominantly fungicidal and was inversely proportional to the pH, being maximal at pH 4.5, the lowest tested pH. Furthermore, antifungal effects of CHOS fractions with varying average molecular weight indicated that those fractions with an intermediate degree of polymerization, i.e. DP 31 and 54, had the strongest inhibitory effects. Confocal imaging showed that C32 adsorbs to the cell surface, with subsequent cell disruption and accumulation of C32 in the cytoplasm. Thus, C32 has potential to be used as a therapy for fungal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.